Showing 4611-4620 of 20465 results for "".
- Finerenone in CKD: Randomized Trial Findingshttps://reachmd.com/news/finerenone-ckd-randomized-trial/2487399/Key Takeaways Finerenone was associated with a slower total eGFR decline, lower albuminuria, and a lower composite kidney-event rate than placebo in this subgroup. The subgroup comprised 903 of 1,584 participants with investigator-reported glomerular d
- SYNCHRONIZE-MASLD Phase 3 Trial Findings on Survodutidehttps://reachmd.com/news/survodutide-synchronize-phase-3-obesity-masld/2487385/Key Takeaways The co-primary endpoints were met, and mean body weight changed by -12.2% with survodutide versus -1.0% with placebo by the efficacy estimand. Broader liver-related and cardiometabolic improvements were observed across liver volume, VCTE
- Low-Dose Rivaroxaban in Advanced CKD: TRACK Trial Resultshttps://reachmd.com/news/low-dose-rivaroxaban-in-advanced-ckd-track-trial-results/2487367/Key Takeaways Low-dose rivaroxaban was not associated with a lower primary cardiovascular composite in adults with advanced CKD, including those receiving dialysis. Major bleeding was more frequent with rivaroxaban than placebo, rising from 6.0% to 8.8
- ECT and MST Trials Show Cognitive Safety Advantage for MSThttps://reachmd.com/news/ect-and-mst-trials-show-cognitive-safety-advantage-for-mst/2487362/Key Takeaways In the larger randomized trial, MST was non-inferior to right unilateral ultra-brief pulse ECT for major depressive disorder. In the smaller bipolar pilot, symptom improvement was broadly similar, while MST showed less autobiographical me
- Digital Stewardship Cut Antibiotic Use for ARIs in Rural Facilitieshttps://reachmd.com/news/digital-stewardship-cut-antibiotic-use-for-aris-in-rural-facilities/2487361/Key Takeaways Antibiotic prescribing was substantially lower in intervention consultations, with adjusted analyses favoring the stewardship program. The intervention was a comprehensive, digitally enabled stewardship program, while control facilities c
- CAN 2409 Plus Radiotherapy Extends Disease-Free Survivalhttps://reachmd.com/news/can-2409-plus-radiotherapy-extends-disease-free-survival/2487363/Key Takeaways Disease-free survival favored CAN 2409 plus valacyclovir over placebo plus valacyclovir during the reported follow-up. Men were randomly assigned 2:1 to three intraprostatic CAN 2409 courses at 5 × 10^11 viral particles plus valacyclovir
- Study: Mineral Sunscreen Whitening Linked to Reduced Application and Protectionhttps://reachmd.com/news/study-links-mineral-sunscreen-whitening-to-reduced-application-and-protection/2487379/New research published in the Journal of Drugs in Dermatology indicates mineral sunscreens produced visible whitening across all skin tones, with a pronounced effect in darker skin tones. Investigators evaluated 5 mi
- Review Examines Glycation’s Expanding Role in Cutaneous Aginghttps://reachmd.com/news/review-examines-glycations-expanding-role-in-cutaneous-aging/2487357/A narrative review published in the Journal of Cosmetic Dermatology examines the growing evidence linking glycation and advanced glycation end products (AGEs) to skin aging, highlighting potential implications for both dermatology and aesthetic medicine. In the review, Diala Hayka
- Corsair Pharma Reports Phase 1 Results for TRX-248 in PAHhttps://reachmd.com/news/corsair-trx-248-pah/2487353/Key Takeaways After single-dose patch use, treprostinil plasma levels remained steady over 24 hours with limited peak-to-trough variation. Corsair reported acceptable safety and skin tolerability, and exposure increased proportionally across patch size
- Perioperative Apalutamide Cuts Metastasis Risk in Proteus Trialhttps://reachmd.com/news/apalutamide-metastasis-risk-proteus/2487349/Key Takeaways The PROTEUS trial met both primary endpoints, with higher pathologic response at surgery and improved metastasis-free survival for the combination regimen. Secondary analyses showed longer time before subsequent therapy and a broader patt